Hyderabad-based pharmaceutical company Bharat Biotech on Friday said it had successfully conducted clinical trials of its potential corona...
Hyderabad-based pharmaceutical company Bharat Biotech on Friday said it had successfully conducted clinical trials of its potential coronavirus vaccine, or Covaxin, on animals. The company said no adverse effects were seen in animals who were immunised with a two-dose regimen of the vaccine.
In a statement released on Friday, the pharmaceutical firm said the data from the study on primates substantiate the immunogenicity of Covaxin. It added that the results demonstrated the protective efficacy of the vaccine in a live viral challenge model.
The company said a two-dose vaccination regimen of inactivated SARS-CoV-2 vaccine candidates was administered in rhesus macaques, a species of the Old World Monkey. Twenty macaques were divided into four groups of five animals each.
While one group was administered with the placebo, three groups were immunised with three different vaccine candidates at zero and 14 days. All the macaques were exposed to viral challenge 14 days after they were given the second dose.
Bharat Biotech proudly announces the animal study results of COVAXIN™ - These results demonstrate the protective efficacy in a live viral challenge model.
— BharatBiotech (@BharatBiotech) September 11, 2020
Read more about the results here - https://t.co/f81JUSfWpD@icmr_niv #BharatBiotech #COVAXIN #Safety #Vaccine #SARSCoV2 pic.twitter.com/fva1SOcLOr
“The results showed protective efficacy, increasing SARS-CoV-2 specific IgG and neutralizing antibodies, reducing replication of the virus in the nasal cavity, throat,...
